The influence of therapeutic category and insurance type on generic substitution of drug products

Journal of Research in Pharmaceutical Economics

Volumn 8, Issue 3, 1997, Pages 3-22

  Mott, David A ^a   Kreling, David H ^b  

^a OHIO STATE UNIVERSITY   (United States)

^b St Luke's Sinai Samaritan Med C   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GENERIC DRUG;

ARTICLE; COST CONTROL; DISEASE DURATION; HEALTH INSURANCE; MEDICAID; PHARMACIST; PHARMACY; PRESCRIPTION; PRIORITY JOURNAL;

EID: 0030953416     PISSN: 08966621     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (21)

1. Goldberg T, DeVito CA, Smith D, et al. Evaluation of economic effects of drug product selection legislation. Med Care 1979;17:411-9.
2. Vuturo GJ, Krischer JP, McCormick WC. Drug product selection: the Florida experience. Am J Public Health 1980;70:479-84.
3. Vuturo GJ, McCormick WC, Krischer JP. Potential and actual drug product selection rates in Florida. Contemp Pharm Pract 1980;3(3):163-70.
4. Stewart JE, Grussing PG, Purohit AA. Drug product selection in Illinois: the first year's experience. Med Care 1982;20:831-42.
5. Shepherd MD, Pongcharoensuk P, Kreling DH. An examination of drug product substitution in Texas two years after enactment of legislation. J Pharm Market Manage 1986;1(2):97-108.
6. Culkin TT, Mendell S. "Generic substitution" in New Jersey, 1979-87. Am Pharm 1989;NS29(2):25-30.
7. Neff A, Simpson T. Drug substitution rate advances: market measures. Drug Top 1992;(Feb 17):16+.
8. Carroll NV, Fincham JE, Cox FM. The effects of differences in state drug product selection laws on pharmacists' substitution behavior. Med Care 1987;25:1069-77.
9. Segal R, Wantz DL, Brusadin RA. Pharmacists' decision making in the selection of generic pharmaceuticals. J Pharm Market Manage 1989;4(1):75-91.
10. Carroll NV, Wolfgang AP. Inherent risk and market acceptance of generic drug products. J Health Care Market 1989;9(4):48-51.
11. Tootelian DH, Gaedeke RM, Schlachter J. Branded versus generic prescription drugs: perceptions of risk, efficacy, safety and value. J Health Care Market 1988;8(3):26-9.
12. Podulka M, Krautkramer K, Amerson D, Phillips B, Dolinsky D. Consumers' attitudes toward generic drugs. J Pharm Market Manage 1989;4(1):93-104.
13. Ganther JM, Kreling DH. Consumer perceptions of generic prescription drugs: an investigation of the relationship between perceived risk and price savings. Unpublished.
14. Bloom BS, Wierz DJ, Pauly MV. Cost and price of comparable branded and generic pharmaceuticals. JAMA 1986;256:2523-30.
15. Vernon JM. Concentration, promotion, and market share stability in the pharmaceutical industry. J Ind Econ 1971;19:246-66.
16. Cocks D, Virts J. Pricing behavior in the ethical pharmaceutical industry. J Business 1974;47:349-62.
17. Hornbrook MC. Market domination and promotional intensity in the wholesale-retail sector of the U.S. pharmaceutical industry. National Center for Health Services Research, Technical Paper Series No. 5, 1976.
18. Hosmer DW, Lemeshow S. Applied logistic regression. New York: John Wiley and Sons, 1989.
19. Hays WL. Statistics. Chicago: Dryden Press, 1988.
20. Mirer TM. Economic statistics and econometrics. New York: Macmillan Publishing Company, 1988.
21. Pauly MV. Doctors and their workshops: economic models of physician behavior. Chicago: Chicago University Press, 1980.